Last reviewed · How we verify
Experimental : Ezetimibe / Rosuvastatin + Telmisartan
This combination reduces cholesterol and blood pressure by inhibiting intestinal cholesterol absorption and HMG-CoA reductase while blocking angiotensin II receptors.
This combination reduces cholesterol and blood pressure by inhibiting intestinal cholesterol absorption and HMG-CoA reductase while blocking angiotensin II receptors. Used for Hypercholesterolemia and hypertension in patients requiring combination therapy, Cardiovascular risk reduction in dyslipidemic hypertensive patients.
At a glance
| Generic name | Experimental : Ezetimibe / Rosuvastatin + Telmisartan |
|---|---|
| Sponsor | Hanlim Pharm. Co., Ltd. |
| Drug class | Combination: Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor + Angiotensin II receptor antagonist |
| Target | Niemann-Pick C1-like 1 (NPC1L1), HMG-CoA reductase, Angiotensin II type 1 receptor (AT1R) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Ezetimibe selectively inhibits cholesterol absorption in the small intestine, while rosuvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis. Telmisartan is an angiotensin II receptor blocker that reduces blood pressure and provides cardiovascular protection. Together, these three agents address multiple cardiovascular risk factors—dyslipidemia and hypertension—in a single formulation.
Approved indications
- Hypercholesterolemia and hypertension in patients requiring combination therapy
- Cardiovascular risk reduction in dyslipidemic hypertensive patients
Common side effects
- Myalgia
- Headache
- Dizziness
- Elevated liver enzymes
- Hyperkalemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: